| [1] |
Siegel RL, Miller KD, Fuchs HE, et al. Cancer Statistics, 2021[J]. CA: Cancer J Clin, 2021, 71(1): 7-33.
|
| [2] |
方友强, 周祥福. 2020版欧洲泌尿外科学会前列腺癌诊疗指南更新要点解读[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2020, 14(6): 401-404.
|
| [3] |
Haffner MC, Zwart W, Roudier MP, et al. Genomic and phenotypic heterogeneity in prostate cancer[J]. Nat Rev Urol, 2021, 18(2): 79-92.
|
| [4] |
Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death[J]. Cell, 2012, 149(5): 1060-1072.
|
| [5] |
Li J, Cao F, Yin H, et al. Ferroptosis: past, present and future[J]. Cell Death Dis, 2020, 11(2): 88.
|
| [6] |
Guerrero-Hue M, García-Caballero C, Palomino-Antolín A, et al. Curcumin reduces renal damage associated with rhabdomyolysis by decreasing ferroptosis‐mediated cell death[J]. FASEB J, 2019, 33(8): 8961-8975.
|
| [7] |
莫建涛,杨沛泽,曹瑞奇,等. 基于生物信息学分析构建肝内胆管细胞癌患者铁死亡相关lncRNA预后模型[J/OL]. 中华肝脏外科手术学电子杂志, 2023, 12(2): 185-189.
|
| [8] |
Liang C, Zhang X, Yang M, et al. Recent progress in ferroptosis inducers for cancer therapy[J]. Advanced Materials ,2019, 31(51): 1904197.
|
| [9] |
Jiang X, Stockwell BR, Conrad M. Ferroptosis: mechanisms, biology and role in disease[J]. Nat Rev Mol Cell Biol, 2021, 22(4): 266-282.
|
| [10] |
Tang D, Chen X, Kang R, et al. Ferroptosis: molecular mechanisms and health implications[J]. Cell Res, 2021, 31(2): 107-125.
|
| [11] |
Stockwell BR, Jiang X, Gu W. Emerging mechanisms and disease relevance of ferroptosis[J]. Trends Cell Biol, 2020, 30(6): 478-490.
|
| [12] |
Mou Y, Wang J, Wu J, et al. Ferroptosis, a new form of cell death: opportunities and challenges in cancer[J]. J Hematol Oncol, 2019, 12(1): 34.
|
| [13] |
Chen X, Kang R, Kroemer G, et al. Broadening horizons: the role of ferroptosis in cancer[J]. Nat Rev Clin Oncol, 2021, 18(5): 280-296.
|
| [14] |
Chen X, Yu C, Kang R, et al. Iron Metabolism in Ferroptosis[J]. Front Cell Dev Biol, 2020, 8: 590226.
|
| [15] |
Yang W, Huang Z, Wu J, et al. A TAZ-ANGPTL4-NOX2 axis regulates ferroptotic cell death and chemoresistance in epithelial ovarian cancer[J]. Mol Cancer Res, 2020, 18(1): 79-90.
|
| [16] |
Zou Y, Li H, Graham ET, et al. Cytochrome P450 oxidoreductase contributes tophospholipid peroxidation in ferroptosis[J]. Nat Cheml Biol, 2020, 16(3): 302-309.
|
| [17] |
Feng H, Schorpp K, Jin J, et al. Transferrin receptor is a specific ferroptosis marker[J]. Cell Rep, 2020, 30(10): 3411-3423.
|
| [18] |
Zheng J, Conrad M. The metabolic underpinnings of ferroptosis[J]. Cell Metab, 2020, 32(6): 920-937.
|
| [19] |
Hassannia B, Vandenabeele P, Vanden Berghe T. Targeting Ferroptosis to Iron Out Cancer[J]. Cancer cell, 2019, 35(6): 830-849.
|
| [20] |
Kuang F, Liu J, Tang D, et al. Oxidative damage and antioxidant defense in ferroptosis[J]. Front Cell Dev Biol, 2020, 8: 969-969.
|
| [21] |
Lei G, Zhang Y, Koppula P, et al. The role of ferroptosis in ionizing radiation-induced cell death and tumor suppression[J]. Cell Res, 2020, 30(2): 146-162.
|
| [22] |
Ding Y, Chen X, Liu C, et al. Identification of a small molecule as inducer of ferroptosis and apoptosis through ubiquitination of GPX4 in triple negative breast cancer cells[J]. J Hematol Oncol, 2021, 14(1): 19.
|
| [23] |
Yao X, Li W, Fang D, et al. Emerging roles of energy metabolism in ferroptosis regulation of tumor cells[J]. Adv Sci (Weinh), 2021, 8(22): 2100997.
|
| [24] |
Shin D, Lee J, You JH, et al. Dihydrolipoamide dehydrogenase regulates cystine deprivation-induced ferroptosis in head and neck cancer[J]. Redox Biol, 2020, 30: 101418.
|
| [25] |
Kang R, Kroemer G, Tang D. The tumor suppressor protein p53 and the ferroptosis network[J]. Free Radic Biol Med, 2019, 133: 162-168.
|
| [26] |
Hafner A, Bulyk M L, Jambhekar A, et al. The multiple mechanisms that regulate p53 activity and cell fate[J]. Nat Rev Mol Cell Biol, 2019, 20(4): 199-210.
|
| [27] |
Doll S, Freitas FP, Shah R, et al. FSP1 is a glutathione-independent ferroptosis suppressor[J]. Nature, 2019, 575(7784): 693-698.
|
| [28] |
Wei X, Yi X, Zhu X, et al. Posttranslational Modifications in Ferroptosis[J]. Oxid Med Cell Longev, 2020, 2020: 1-12.
|
| [29] |
Moussa M, Papatsoris A, Abou Chakra M, et al. Pharmacotherapeutic strategies for castrate-resistant prostate cancer[J]. Expert Opin Pharmacother, 2020, 21(12): 1431-1448.
|
| [30] |
Bordini J, Morisi F, Elia AR, et al. Iron induces cell death and strengthens the efficacy of antiandrogen therapy in prostate cancer models[J]. Clin Cancer Res, 2020, 26(23): 6387-6398.
|
| [31] |
Nie Z, Chen M, Gao Y, et al. Regulated cell death in urinary malignancies[J]. Front Cell Dev Biol, 2021, 9: 789004..
|
| [32] |
Bader DA, Mcguire SE. Tumour metabolism and its unique properties in prostate adenocarcinoma[J]. Nat Rev Urol, 2020, 17(4): 214-231.
|
| [33] |
朱芝静, 姜依凡, 张迪泽, 等. Sorafenib通过诱导铁死亡抑制DU145前列腺癌细胞增殖的分子机制[J]. 现代泌尿外科杂志, 2021, 26(9): 780-784.
|
| [34] |
Blomme A, Ford CA, Mui E, et al. 2,4-dienoyl-CoA reductase regulates lipid homeostasis in treatment-resistant prostate cancer[J]. Nat Commun, 2020, 11(1): 2508.
|
| [35] |
Nassar ZD, Mah CY, Dehairs J, et al. Human DECR1 is an androgen-repressed survival factor that regulates PUFA oxidation to protect prostate tumor cells from ferroptosis[J]. ELife, 2020, 9: e54166.
|
| [36] |
Tousignant KD, Rockstroh A, Poad BLJ, et al. Therapy-induced lipid uptake and remodeling underpin ferroptosis hypersensitivity in prostate cancer[J]. Cancer Metab, 2020, 8(1):11.
|
| [37] |
Ghoochani A, Hsu E, Aslan M, et al. Ferroptosis inducers are a novel therapeutic approach for advanced prostate cancer[J]. Cancer Res, 2021, 81(6): 1583-1594.
|
| [38] |
Yang Y, Liu T, Hu C, et al. Ferroptosis inducer erastin downregulates androgen receptor and its splice variants in castrationresistant prostate cancer[J]. Oncol Rep, 2021, 45(4): 25.
|
| [39] |
Qin Z, Ou S, Xu L, et al. Design and synthesis of isothiocyanate‐containing hybrid androgen receptor (AR) antagonist to downregulate AR and induce ferroptosis in GSH-Deficient prostate cancer cells[J]. Chem Biol Drug Des, 2021, 97(5): 1059-1078.
|
| [40] |
Li M, Chen X, Wang X, et al. RSL3 enhances the antitumor effect of cisplatin on prostate cancer cells via causing glycolysis dysfunction[J]. Biochem Pharmacol, 2021, 192: 114741.
|
| [41] |
He S, Zhang M, Ye Y, et al. ChaC glutathione specific gamma-glutamylcyclotransferase 1 inhibits cell viability and increases the sensitivity of prostate cancer cells to docetaxel by inducing endoplasmic reticulum stress and ferroptosis[J]. Exp Ther Med, 2021, 22(3): 997.
|